U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Add as a preferred source on Google
INDIAN WELLS, Calif., April 06, 2018 -- Nova Oculus Partners, LLC today issued the following statement from its founder Peter Pocklington:
I am extremely proud of what we have accomplished in a short time.
I founded Nova Oculus four years ago because I firmly believe the microcurrent electro-therapy technology behind our medical device successfully mitigates symptoms of the dry version of Age-Related Macular Degeneration.
I personally suffer from AMD, and my experience with early prototypes of our device attests to its promise. And I’m not the only one.
We have a blue-ribbon team of professionals leading our efforts to bring Nova Oculus to market. We also assembled a medical advisory board that includes some of the leading optometric professionals in the United States to develop a plan to earn FDA approval and widespread commercialization in the U.S.
Our device is currently being considered for a medical license by the Canadian government regulator, Health Canada, for commercialization in that country. It also is undergoing a clinical trial with patient test groups in Calgary, Canada.
Our Nova Oculus device has been certified by the International Organization of Standardization (ISO) as complying with quality control and safety in its development, and by the International Electrotechnical Commission, which gave its approval for the device’s electrical safety. These certifications pave the way for global regulatory approvals for Nova Oculus.
The real story of Nova Oculus is our promising technology, our brilliant team and our achievements. This created credibility for the company and faith by investors.
The SEC’s announcement was a laundry list of misguided accusations based on unrelated items of dubious interest. We intend to vigorously defend our reputation. We will fight to bring the Nova Oculus medical device to market. It’s the right thing to do.
AMD has no cure. It is the leading cause of blindness in North America. More than 14 million people suffer from this affliction — a figure that is expected to double as baby boomers age.
Our goal is unwavering. We will do all we can to restore sight to people who would otherwise not have any.
That is my promise to you.
Peter Pocklington
Founder, Nova Oculus
Contact:
Sonya Bucher
[email protected]
(323) 399-1166
